Profile data is unavailable for this security.
About the company
Agilent Technologies, Inc. is engaged in providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. It operates in the life sciences, diagnostics and applied chemical markets. Its life sciences and applied markets segment provides application-focused solutions that include instruments, consumables and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Its diagnostics and genomics segment includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses. The Agilent CrossLab segment offers a service portfolio that includes repairs, parts, maintenance, installations and various other custom services to support the laboratory operations. It also offers contract development and manufacturing organization (CDMO) services.
- Revenue in USD (TTM)6.50bn
- Net income in USD1.41bn
- Incorporated1999
- Employees17.40k
- LocationAgilent Technologies Inc5301 Stevens Creek BlvdSANTA CLARA 95051United StatesUSA
- Phone+1 (408) 345-8886
- Fax+1 (408) 345-8474
- Websitehttps://www.agilent.com/
More ▼
Mergers & acquisitions
| Acquired company | A:NYQ since announced | Transaction value |
|---|---|---|
| Sigsense Technologies Inc | -6.37% | -- |
| BioVectra Inc | -2.44% | 925.00m |
Data delayed at least 15 minutes, as of Nov 21 2024.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cooper Companies Inc | 3.80bn | 359.30m | 19.73bn | 15.00k | 55.18 | 2.49 | 26.81 | 5.19 | 1.80 | 1.80 | 19.02 | 39.80 | 0.3196 | 1.70 | 5.56 | 253,606.70 | 3.02 | 10.06 | 3.29 | 11.34 | 66.36 | 65.54 | 9.45 | 29.00 | 1.18 | 5.46 | 0.2493 | 0.3469 | 8.61 | 7.24 | -23.74 | -3.66 | 15.18 | 0.00 |
| Illumina Inc | 4.39bn | -1.58bn | 20.88bn | 10.59k | -- | 9.85 | -- | 4.76 | -10.00 | -10.00 | 27.61 | 13.36 | 0.5441 | 2.66 | 6.17 | 414,542.00 | -19.63 | -6.20 | -23.16 | -7.28 | 63.94 | 66.39 | -36.08 | -15.48 | 1.85 | 38.44 | 0.4834 | -- | -1.75 | 6.21 | 73.64 | -- | -7.91 | -- |
| Steris PLC | 5.12bn | 602.62m | 20.95bn | 18.18k | 34.93 | 3.18 | 18.92 | 4.09 | 6.08 | 4.38 | 51.62 | 66.80 | 0.4758 | 3.86 | 5.49 | 281,655.40 | 5.62 | 5.19 | 6.10 | 5.68 | 43.01 | 43.64 | 11.81 | 10.97 | 1.55 | 8.29 | 0.2528 | 36.56 | 13.28 | 13.06 | -1.07 | 12.67 | 13.69 | 8.83 |
| Waters Corp | 2.91bn | 622.64m | 21.24bn | 7.90k | 34.14 | 13.25 | 26.07 | 7.31 | 10.48 | 10.48 | 48.89 | 27.00 | 0.645 | 2.20 | 4.47 | 367,740.10 | 13.82 | 19.77 | 16.72 | 25.29 | 59.73 | 58.45 | 21.43 | 23.38 | 1.38 | 10.11 | 0.5325 | 0.00 | -0.5229 | 4.09 | -9.26 | 1.53 | 4.72 | -- |
| Zimmer Biomet Holdings Inc | 7.60bn | 1.08bn | 21.75bn | 18.00k | 20.81 | 1.76 | 10.57 | 2.86 | 5.25 | 5.25 | 36.87 | 62.00 | 0.3538 | 0.9136 | 5.38 | 421,972.20 | 5.05 | 2.21 | 5.82 | 2.52 | 71.78 | 71.25 | 14.28 | 7.28 | 0.6987 | 7.52 | 0.3425 | 38.90 | 6.55 | -1.40 | 252.86 | -- | 9.44 | 0.00 |
| West Pharmaceutical Services Inc. | 2.88bn | 499.60m | 22.57bn | 10.60k | 46.18 | 8.21 | 35.59 | 7.85 | 6.75 | 6.75 | 38.86 | 37.96 | 0.7743 | 4.50 | 5.51 | 271,358.50 | 13.02 | 15.61 | 15.16 | 18.65 | 34.87 | 38.06 | 16.81 | 18.47 | 2.23 | -- | 0.0695 | 10.69 | 2.18 | 11.43 | 2.28 | 23.76 | 28.16 | 6.20 |
| DexCom Inc | 3.95bn | 680.80m | 29.39bn | 9.60k | 45.93 | 14.85 | 32.90 | 7.43 | 1.64 | 1.64 | 9.52 | 5.07 | 0.6107 | 2.76 | 4.42 | 411,875.00 | 10.51 | 8.30 | 14.28 | 10.50 | 62.10 | 65.90 | 17.22 | 14.14 | 2.12 | -- | 0.5579 | 0.00 | 24.49 | 28.56 | 58.70 | -- | 28.66 | -- |
| Veeva Systems Inc | 2.57bn | 615.26m | 34.11bn | 7.17k | 54.65 | 6.57 | 52.33 | 13.25 | 3.85 | 3.85 | 15.69 | 32.04 | 0.4453 | -- | 6.27 | 358,846.80 | 10.65 | 11.97 | 12.97 | 15.36 | 73.35 | 72.00 | 23.91 | 23.74 | -- | -- | 0.00 | 0.00 | 9.68 | 22.35 | 7.79 | 18.00 | 21.68 | -- |
| IDEXX Laboratories, Inc. | 3.84bn | 866.24m | 34.28bn | 11.00k | 40.39 | 21.22 | 34.55 | 8.92 | 10.36 | 10.36 | 46.00 | 19.72 | 1.19 | 3.85 | 7.14 | 349,528.80 | 26.91 | 28.00 | 38.86 | 43.49 | 60.72 | 58.74 | 22.53 | 21.35 | 1.03 | 59.10 | 0.3507 | 0.00 | 8.72 | 10.59 | 24.44 | 17.39 | 1.68 | -- |
| Resmed Inc | 4.81bn | 1.11bn | 35.46bn | 9.98k | 32.02 | 6.82 | 27.50 | 7.38 | 7.54 | 7.54 | 32.59 | 35.39 | 0.6886 | 2.17 | 6.08 | 481,711.90 | 15.94 | 14.24 | 18.11 | 16.53 | 57.67 | 56.85 | 23.15 | 20.35 | 1.91 | 44.71 | 0.1154 | 32.62 | 10.95 | 12.44 | 13.75 | 19.98 | 8.23 | 5.34 |
| Agilent Technologies Inc | 6.50bn | 1.41bn | 36.94bn | 17.40k | 26.74 | 6.26 | 22.21 | 5.69 | 4.81 | 4.81 | 22.14 | 20.53 | 0.5996 | 2.87 | 5.06 | 358,950.30 | 13.04 | 11.00 | 16.13 | 13.25 | 54.75 | 53.29 | 21.75 | 18.01 | 1.37 | 55.86 | 0.3319 | 21.46 | -0.219 | 6.82 | -1.12 | 7.39 | 10.98 | 8.86 |
| GE HealthCare Technologies Inc | 19.56bn | 1.68bn | 38.79bn | 51.00k | 23.25 | 4.66 | 16.77 | 1.98 | 3.65 | 3.65 | 42.63 | 18.20 | 0.5906 | 5.40 | 4.41 | 383,490.20 | 5.22 | -- | 6.97 | -- | 41.33 | -- | 8.84 | -- | 0.982 | 5.67 | 0.5478 | -- | 6.60 | -- | -26.82 | -- | -- | -- |
| Edwards Lifesciences Corp | 5.62bn | 1.43bn | 41.01bn | 19.80k | 29.37 | 4.30 | 26.26 | 7.30 | 2.37 | 6.93 | 9.32 | 16.18 | 0.5032 | 1.12 | 7.72 | 283,904.00 | 12.76 | 16.63 | 14.98 | 19.12 | 78.63 | 76.71 | 25.35 | 24.84 | 2.89 | -- | 0.0585 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
| Cencora Inc | 293.96bn | 1.51bn | 47.92bn | 42.00k | 32.40 | 60.91 | 18.18 | 0.163 | 7.51 | 7.51 | 1,467.70 | 3.99 | 4.53 | 15.59 | 12.44 | -- | 2.34 | 1.12 | 11.51 | 4.83 | 3.35 | 3.25 | 0.5168 | 0.2556 | 0.5291 | 19.37 | 0.848 | 65.38 | 12.12 | 10.36 | -13.53 | 13.02 | 9.45 | 4.98 |
Data as of Nov 21 2024. Currency figures normalised to Agilent Technologies Inc's reporting currency: US Dollar USD
39.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 32.15m | 11.19% |
| Massachusetts Financial Services Co.as of 30 Sep 2024 | 15.59m | 5.43% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 15.57m | 5.42% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 12.82m | 4.46% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 8.44m | 2.94% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2024 | 8.24m | 2.87% |
| Geode Capital Management LLCas of 30 Sep 2024 | 6.95m | 2.42% |
| Pictet Asset Management SAas of 30 Sep 2024 | 5.17m | 1.80% |
| State Farm Investment Management Corp.as of 30 Sep 2024 | 3.83m | 1.33% |
| BlackRock Investment Management (UK) Ltd.as of 30 Sep 2024 | 3.79m | 1.32% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
